Insulin maker Sanofi-Aventis took a big hit last year with the Lantus-cancer scare. But that hasn’t stopped them from charging ahead in diabetes care. According to industry observers, the company’s new US Diabetes unit, fueled by a recent “acquisi…
SOURCE: Healthline RSS Feed – Read entire story here.